Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 10/20 | 0.62 |
| ▸ | KLK3 | P07288 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TYMS | P04818 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | C1R | P00736 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | MPI | P34949 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15519149 | 0.90 | ELANE (0.50) | ELANEKLK3ALDH1A1TYMSMEN1 | |
| SCHEMBL10662992 | 0.81 | ELANE (0.63) | ELANEKLK3ALDH1A1TYMSMEN1 | |
| SCHEMBL5441389 | 0.80 | ALDH1A1 (0.52) | ELANEKLK3ALDH1A1MEN1KMT2A | |
| SCHEMBL31489848 | 0.78 | MEN1 (0.58) | ELANEKLK3ALDH1A1MEN1KMT2A | |
| SCHEMBL912480 | 0.78 | KMT2A (0.73) | ELANEKLK3ALDH1A1MEN1KMT2A | |
| SCHEMBL17770598 | 0.78 | MEN1 (0.58) | ELANEKLK3ALDH1A1MEN1KMT2A | |
| SCHEMBL26672077 | 0.77 | TYMS (0.42) | ELANEKLK3ALDH1A1TYMSMEN1 | |
| SCHEMBL282843 | 0.77 | ELANE (1.00) | ELANEC1R | |
| SCHEMBL16213278 | 0.77 | TDP1 (0.46) | KLK3ALDH1A1TYMSMEN1KMT2A | |
| SCHEMBL20423396 | 0.77 | ELANE (0.64) | ELANEKLK3ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2991976-B1 | SYNTHESIS OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL) PIPERIDINE-2,6-DIONE | CELGENE CORP (US) | 2017-09-20 | — | — | EP | claimed |
| EP-2991976-A1 | SYNTHESIS OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL) PIPERIDINE-2,6-DIONE | Celgene Corporation (US) | 2016-03-09 | — | — | EP | claimed |
| US-9266858-B2 | Synthesis of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione | CELGENE CORPORATION (US) | 2016-02-23 | — | — | US | claimed |
| US-20150274694-A1 | SYNTHESIS OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL)PIPERIDINE-2,6-DIONE | CELGENE CORP (US) | 2015-10-01 | — | — | US | claimed |
| US-20150203469-A1 | ISOTOPOLOGUES OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL) PIPERIDINE-2-6-DIONE AND METHODS OF PREPARATION THEREOF | CELGENE CORPORATION | 2015-07-23 | — | — | US | claimed |
| EP-2892887-A1 | ISOTOPOLOGUES OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL) PIPERIDINE-2-6-DIONE AND METHODS OF PREPARATION THEREOF | Celgene Corporation (US) | 2015-07-15 | — | — | EP | claimed |
| US-9067912-B2 | Synthesis of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,8-dione | CELGENE CORPORATION (US) | 2015-06-30 | — | — | US | claimed |
| US-20140330016-A1 | SYNTHESIS OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL)PIPERIDINE-2,6-DIONE | CELGENE CORPORATION (US) | 2014-11-06 | — | — | US | claimed |
| WO-2014179416-A1 | SYNTHESIS OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL) PIPERIDINE-2,6-DIONE | CELGENE CORPORATION (US) | 2014-11-06 | — | — | WO | claimed |
| WO-2014039421-A1 | ISOTOPOLOGUES OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL) PIPERIDINE-2-6-DIONE AND METHODS OF PREPARATION THEREOF | CELGENE CORPORATION (US) | 2014-03-13 | — | — | WO | claimed |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20250382240-A1 | 3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | SALARIUS PHARMACEUTICALS INC (US) | 2025-12-18 | — | — | US | disclosed |
| WO-2024220489-A1 | DEUTERIUM-ENRICHED COMPOUND FOR USE IN A METHOD OF TREATMENT OF MULTIPLE MYELOMA | SALARIUS PHARMACEUTICALS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024148164-A1 | SOLID FORMS AND METHODS OF USE | SALARIUS PHARMACEUTICALS, INC (US) | 2024-07-11 | — | — | WO | disclosed |
| US-11820720-B2 | 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deuteropiperidine-2,6-dione derivatives and compositions comprising and methods of using the same | SALARIUS PHARMACEUTICALS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20100093774-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION. | 2010-04-15 | — | — | US | disclosed |
| US-7635700-B2 | e.g. 3-(5-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE; cytokine (epidermal/fibroblast/endothelial/tumor necrosis growth factors) antagonist; antitumor, antiinflammatory agent, neurodegenerative diseases | CELGENE CORPORATION (US) | 2009-12-22 | — | — | US | disclosed |
| EP-2066656-A2 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AS ANTITUMOR AGENTS | CELGENE CORPORATION (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20080161328-A1 | e.g. 3-(5-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE; cytokine (epidermal/fibroblast/endothelial/tumor necrosis growth factors) antagonist; antitumor, antiinflammatory agent, neurodegenerative diseases | CELGENE CORPORATION | 2008-07-03 | — | — | US | disclosed |
| WO-2008039489-A2 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AS ANTITUMOR AGENTS | CELGENE CORPORATION (US) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203469-A1 | ISOTOPOLOGUES OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL) PIPERIDINE-2-6-DIONE AND METHODS OF PREPARATION THEREOF | AQP3, CYP2D6, CYP3A5 | ELANE 4693/4885KLK3 720/4885ALDH1A1 1628/4885 |
| US-20140330016-A1 | SYNTHESIS OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL)PIPERIDINE-2,6-DIONE | AZI2, DHPS, PKD2 | ELANE 4613/4885KLK3 1951/4885ALDH1A1 1399/4885 |
| US-20150274694-A1 | SYNTHESIS OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL)PIPERIDINE-2,6-DIONE | AZI2, DHPS, PKD2 | ELANE 4613/4885KLK3 1951/4885ALDH1A1 1399/4885 |
| US-11820720-B2 | 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deuteropiperidine-2,6-dione derivatives and compositions comprising and methods of using the same | IL5, IL15, CXCR5 | ELANE 1051/4885KLK3 139/4885ALDH1A1 2572/4885 |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | ADRM1, UCHL3, USP30 | ELANE 1337/4885KLK3 4514/4885ALDH1A1 3506/4885 |
| US-20080161328-A1 | e.g. 3-(5-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE; cytokine (epidermal/fibroblast/endothelial/tumor necrosis growth factors) antagonist; antitumor, antiinflammatory agent, neurodegenerative diseases | FGF2, TNF, FGF1 | ELANE 134/4885KLK3 2279/4885ALDH1A1 2470/4885 |
| US-20250382240-A1 | 3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | IL5, TLR5, IDO1 | ELANE 1346/4885KLK3 139/4885ALDH1A1 1594/4885 |
| US-20100093774-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | IL5, IL6, PGF | ELANE 1183/4885KLK3 2726/4885ALDH1A1 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.